VintaBio Capacity Update October 2024: Cell & Gene Therapy

Jennifer Kingsley, Chief Commercial Officer at VintaBio, a Philadelphia-based contract manufacturing organization in the cell and gene therapy hub, recently presented how VintaBio has expanded AAV clinical manufacturing capacity through its proprietary VintaProcess platform.

This intensified adherent AAV process achieves notably high yields and purity levels — exceeding 95% full capsids — while using a compact, scalable footprint that outperforms traditional suspension methods. Review the slideshow below to see how the VintaProcess platform supports accelerated gene therapy timelines by delivering efficient, high-quality manufacturing solutions that meet the growing demand in this field.